The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL

miR-21 expression in cancer tissue has been reported to be associated with the clinical outcome and activity of gemcitabine in pancreatic cancer. However, resection is possible in only a minority of patients due to the advanced stages often present at the time of diagnosis, and safely obtaining suff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular oncology 2013-06, Vol.7 (3), p.334-345
Hauptverfasser:	Wang, Peng, Zhuang, Liping, Zhang, Juan, Fan, Jie, Luo, Jianmin, Chen, Hao, Wang, Kun, Liu, Luming, Chen, Zhen, Meng, Zhiqiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced pancreatic cancer Antimetabolites, Antineoplastic - pharmacology Antimetabolites, Antineoplastic - therapeutic use Apoptosis Apoptosis - drug effects Base Sequence Binding sites Cancer therapies Chemoresistance Chemosensitivity Chemotherapy Cohort Studies Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Deoxycytidine - therapeutic use Drug Resistance, Neoplasm Ectopic expression Fas Ligand Protein - genetics Fas Ligand Protein - metabolism FasL FasL protein Gemcitabine Gene expression Gene Expression Regulation, Neoplastic - drug effects Hospitals Humans Male Medical prognosis Metastasis MicroRNAs MicroRNAs - blood MicroRNAs - genetics NMR Nuclear magnetic resonance Pancreas - drug effects Pancreas - metabolism Pancreas - pathology Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Prognosis Proteins Serum miR-21 Studies Tumors
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!